Short answer
Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Press release covers Editas Medicine’s quarter ended June 30, 2026 financial results.
Editas Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Editas Medicine’s quarter ended June 30, 2026 financial results
- Exhibit 99.1 contains business highlights and detailed quarterly results
Item 5.02 · Departure/Election of Directors or Officers
- Elliott Levy resigned as class I director effective August 4, 2026, without disagreement with Editas Medicine
- Patrick Ellinor appointed independent class I director effective August 6, 2026
- Ellinor brings senior cardiovascular leadership from Mass General Brigham, Harvard Medical School, and Broad Institute
- Annual board cash compensation of $40,000 plus option for 103,400 shares
- Option vests in three equal installments over three anniversaries, with exercise price set at appointment-date closing price
Item EX-99.1 · Exhibit EX-99.1
- EDIT-401 CTN submission targeted for August 2026, with Phase 1/2 data update expected in Q1 2027
- Preclinical EDIT-401 data showed approximately 90% or greater reductions in LDL-C, Lp(a), and ApoB in non-human primates
- Cash $211.6M at June 30, 2026, supporting operations into the second half of 2028
- May financing generated $125.0M gross proceeds, with approximately $194.4M potential from warrant exercises
- Q2 net loss $18.2M, or $0.15 per share, versus $53.2M, or $0.63 per share, in Q2 2025
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Editas Medicine, Inc. 8-K filings
Get the next EDIT 8-K as it lands
Follow EDIT for push alerts, or ask the research agent what this filing means.